Topical skin components

Abstract

The present invention provides a topical skin composition containing dissolved azelaic acid, wherein the precipitation of azelaic acid over time is suppressed. [Solution] A topical skin composition comprising (A) azelaic acid, (B-1) an amide derivative of azelaic acid, (B-2) a dicarboxylic acid or salt thereof having 5 to 10 carbon atoms (excluding component (A)), and (B-3) at least one compound selected from the group consisting of compounds having a pyrrolidone ring group.

Description

[Technical Field]

[0001] This invention relates to a composition for external use on the skin. [Background technology]

[0002] Azelaic acid is a compound that has been used as an active ingredient in acne treatments. Patent Document 1 describes a cream or emulsion containing azelaic acid. [Prior art documents] [Patent Documents]

[0003] [Patent Document 1] Patent No. 5734686 [Overview of the project] [Problems that the invention aims to solve]

[0004] Azelaic acid is poorly soluble in water, making it difficult to incorporate into formulations with a high water content, such as lotions. Furthermore, dissolving azelaic acid raises concerns about precipitation over time or under extreme temperature conditions. Therefore, conventional formulations containing azelaic acid primarily involve dispersing it in a high-viscosity emulsion without dissolving it.

[0005] Therefore, the present invention aims to provide a topical skin composition in which azelaic acid is dissolved, and in which the precipitation of azelaic acid over time is suppressed. [Means for solving the problem]

[0006] As a result of diligent research, the inventors discovered that by adding a specific component to a solution containing azelaic acid, it is possible to suppress the precipitation of azelaic acid over time, and furthermore, precipitation under harsh temperature conditions, thus completing the present invention.

[0007] The present invention includes, for example, the following inventions. [1] A topical skin composition comprising (A) azelaic acid, (B-1) an amide derivative of azelaic acid, (B-2) a dicarboxylic acid or salt thereof having 5 to 10 carbon atoms (excluding component (A)), and (B-3) a compound having a pyrrolidone ring group. [2] The topical skin composition according to [1], wherein component (B-1) is at least one selected from the group consisting of reaction products of azelaic acid with an amino acid or peptide compound and salts thereof, azelaic acid amidoamine compounds, and azelaic acid alcoholamine compounds. [3] The topical skin composition according to [1] or [2], wherein component (B-1) is at least one selected from the group consisting of potassium azeroyl diglycine, azelaic acid lysine, azera oil bisdipeptide-10, azera oil tripeptide-1, azeramidopropyl dimethylamine, and azeramido monoethanolamine. [4] A topical skin composition according to any one of [1] to [3], wherein the number of carbon atoms in component (B-2) is 5 or more and 8 or less. [5] The topical skin composition according to any one of [1] to [4], wherein component (B-3) is at least one selected from the group consisting of pyrrolidone carboxylic acid or a salt thereof and polyvinylpyrrolidone. [6] The skin composition according to any one of [1] to [5], wherein the mass ratio of the content of component (B-1) to the content of component (A) is 0.5 or more and 20 or less. [7] The skin composition according to any one of [1] to [6], wherein the mass ratio of the content of component (B-2) to the content of component (A) is 0.5 or more and 10 or less. [8] A topical skin composition according to any one of [1] to [7], wherein the mass ratio of the content of component (B-3) to the content of component (A) is 0.5 or more and 5 or less. [9] The topical skin composition according to any one of [1] to [8], wherein component (A) is dissolved in the topical skin composition.

[10] (C) A topical skin composition according to any one of [1] to [9], further comprising at least one selected from the group consisting of a dihydric alcohol having 3 or more carbon atoms and a monohydric alcohol having 2 or 3 carbon atoms.

[11] A topical skin composition according to any one of [1] to

[10] , wherein the pH is 2 or higher and 6 or lower.

[12] A method for inhibiting the precipitation of azelaic acid in a topical skin composition, comprising the coexistence of (A) azelaic acid, (B-1) an amide derivative of azelaic acid, (B-2) a dicarboxylic acid or salt thereof having 5 to 10 carbon atoms (excluding component (A)), and (B-3) a compound having a pyrrolidone ring group in the topical skin composition.

[13] A method for assisting the dissolution of azelaic acid in a topical skin composition, comprising the coexistence of (A) azelaic acid and at least one selected from the group consisting of (B-1) an amide derivative of azelaic acid, (B-2) a dicarboxylic acid or salt thereof having 5 to 10 carbon atoms (excluding component (A)), and (B-3) a compound having a pyrrolidone ring group in the topical skin composition. [Effects of the Invention]

[0008] According to the present invention, a topical skin composition containing dissolved azelaic acid is provided, in which the precipitation of azelaic acid over time is suppressed. [Modes for carrying out the invention]

[0009] The embodiments for carrying out the present invention will be described in detail below. However, the present invention is not limited to the following embodiments.

[0010] In the numerical ranges described stepwise in this specification, the upper or lower limit of one step in the numerical range may be arbitrarily combined with the upper or lower limit of another step in the numerical range. In the numerical ranges described in this specification, the upper or lower limit of that numerical range may be replaced with the values ​​shown in the examples. Unless otherwise specified, the components or materials exemplified in this specification may be used individually or in combination of two or more.

[0011] The topical skin composition according to this embodiment contains (A) azelaic acid, (B-1) an amide derivative of azelaic acid, (B-2) a dicarboxylic acid or salt thereof having 5 to 10 carbon atoms (excluding component (A)), and (B-3) at least one compound selected from the group consisting of compounds having a pyrrolidone ring group.

[0012] In compositions containing azelaic acid in a dissolved state, a problem arises because azelaic acid tends to precipitate during storage. However, the topical skin composition according to this embodiment contains at least one compound selected from the group consisting of (B-1) an amide derivative of azelaic acid, (B-2) a dicarboxylic acid or salt thereof having 5 to 10 carbon atoms (excluding component (A)), and (B-3) a compound having a pyrrolidone ring group, thereby suppressing the precipitation of (A) azelaic acid over time. In particular, the topical skin composition according to this embodiment suppresses the precipitation of azelaic acid not only when the composition is stored at room temperature, but also when it is stored in a low-temperature environment (e.g., 4°C) where precipitation is more likely to occur. Therefore, the topical skin composition according to this embodiment can be said to be a composition with excellent storage stability.

[0013] Furthermore, the topical skin composition according to this embodiment also has the effect of making (A) azelaic acid more easily soluble in a water-containing medium by containing at least one selected from the group consisting of (B-1) an amide derivative of azelaic acid, (B-2) a dicarboxylic acid or salt thereof having 5 to 10 carbon atoms (excluding component (A)), and (B-3) a compound having a pyrrolidone ring group.

[0014] (A) Azelaic acid (hereinafter also referred to as "component (A)") has the chemical formula C9H 16 It is a saturated dicarboxylic acid represented by O4 and a compound represented by the following formula (1). Component (A) is preferably present dissolved in the external skin composition according to the present embodiment.

[0015]

Chemical Formula

[0016] The content of component (A), based on the total amount of the external skin composition, may be 0.05 mass% or more, 0.1 mass% or more, 0.3 mass% or more, 1 mass% or more, or 3 mass% or more, and may be 25 mass% or less, 20 mass% or less, 15 mass% or less, 10 mass% or less, 8 mass% or less, or 5 mass% or less.

[0017] (B-1) Amide derivative of azelaic acid (hereinafter also referred to as "component (B-1)") refers to a compound wherein, among the two carboxyl groups of azelaic acid represented by the above formula (1), one or two carboxyl groups are substituted with a group represented by the following formula (2) or a group represented by the following formula (3).

[0018]

Chemical Formula

[0019]

Chemical Formula

[0020] Component (B-1) may be at least one selected from the group consisting of reaction products of azelaic acid with an amino acid or peptide compound and their salts, azelaic acid amidoamine compounds, and azelaic acid alcoholamine compounds.

[0021] Reaction products of azelaic acid and amino acids include, for example, salts of azelaic acid and amino acids, and amides or diamides of azelaic acid and amino acids.

[0022] The amino acids in the reaction product of azelaic acid and amino acids are preferably glycine, lysine, alanine, histidine, and arginine, and more preferably glycine and lysine. When the reaction product of azelaic acid and amino acids is the reaction product of azelaic acid and two amino acids, the two amino acids may be the same or different.

[0023] More specifically, examples of salts of azelaic acid and amino acids include azelaic acid lysine, which is a salt of azelaic acid and lysine.

[0024] The salt of the reaction product between azelaic acid and an amino acid may be, for example, a salt of an amide or diamide of azelaic acid and an amino acid. In this case, the salt may be a metal salt such as a potassium salt or a sodium salt, or an inorganic salt such as a triethanolamine salt or an ammonium salt. More specifically, examples of salts of amides or diamides of azelaic acid and amino acids include potassium azeroyldiglycine (azeroyldiglycine K), which is the potassium salt of the diamide of azelaic acid and glycine.

[0025] The reaction product of azelaic acid and a peptide compound, and the salt of the reaction product of azelaic acid and a peptide compound, refer to the compound formed by the bonding of azelaic acid and a peptide compound, and the salt thereof. The peptide compound may be a dipeptide, tripeptide, or polypeptide.

[0026] More specifically, reaction products of azelaic acid and peptide compounds include azela oil bisdipeptide-10, which is a reaction product of azelaic acid with a dipeptide consisting of alanine and histidine, and azela oil tripeptide-1, which is a reaction product of azelaic acid with a tripeptide consisting of glycine, histidine, and lysine.

[0027] The salt of the reaction product between azelaic acid and a peptide compound may be a metal salt such as a potassium salt or a sodium salt, or an inorganic salt such as a triethanolamine salt or an ammonium salt.

[0028] Azelaic acid amidoamine compounds are, for example, compounds represented by the following formula (4).

[0029] [ka] [In formula (4), R 3 R is a linear or branched alkylene group, 4 and R 5 Each of these independently represents either a hydrogen atom or a methyl group.

[0030] R in equation (4) 3 The number of carbon atoms in the alkylene group represented by may be 1 or more, 2 or more, 6 or less, 5 or less, 4 or less, or 3. The alkylene group is preferably an n-propylene group.

[0031] More specifically, examples of azelaic acid amidoamine compounds include azeramidopropyldimethylamine, which is represented by the following formula (4-1).

[0032] [ka]

[0033] Azelaic acid alcoholamine compounds are, for example, compounds represented by the following formula (5).

[0034]

Chem.

[0035] R in formula (5) 6 the alkylene group represented by may have 1 or more carbon atoms, may have 5 or less, 4 or less, or 3 or less carbon atoms, and may have 2 carbon atoms. The alkylene group is preferably an ethylene group.

[0036] More specific examples of the azelaic acid alcoholamine compound include azelamide monoethanolamine represented by the following formula (5-1).

[0037]

Chem.

[0038] From the viewpoint of further enhancing the effect of the present invention, component (B-1) is preferably at least one selected from the group consisting of reaction products of azelaic acid with amino acids and salts thereof, reaction products of azelaic acid with peptide compounds, and amidoamine compounds of azelaic acid, and more preferably at least one selected from the group consisting of potassium azelaoyl diglycinate, azeloyl bis dipeptide-10, and azelamidopropyl dimethylamine.

[0039] From the viewpoint of further enhancing the effect of the present invention, the content of component (B-1), based on the total mass of the external composition for skin, is preferably 0.001 mass% or more, 0.01 mass% or more, 0.1 mass% or more, 0.5 mass% or more, 1 mass% or more, 1.5 mass% or more, 2 mass% or more, or 4 mass% or more, and is preferably 20 mass% or less, 15 mass% or less, 10 mass% or less, 5 mass% or less, 3 mass% or less, or 1 mass% or less.

[0040] The mass ratio of the content of component (B-1) to the content of component (A) {content of component (B-1) / content of component (A)} is preferably 0.001 or more, 0.005 or more, 0.01 or more, 0.5 or more, 1 or more, 1.5 or more, 2 or more, or 4 or more, and also preferably 20 or less, 17 or less, 15 or less, or 10 or less.

[0041] (B-2) In a dicarboxylic acid or salt thereof having 5 to 10 carbon atoms (excluding component (A) above) (hereinafter also referred to as "component (B-2)"), the dicarboxylic acid may be an aliphatic dicarboxylic acid or an aromatic dicarboxylic acid, but is preferably an aliphatic dicarboxylic acid.

[0042] The number of carbon atoms in component (B-2) is preferably 5 or more, or 6 or more, and also preferably 8 or less, or 6 or less, from the viewpoint of further enhancing the effects of the present invention. The number of carbon atoms in component (B-2) may be 6 or 8.

[0043] (B-2) Component is more preferably adipic acid, which is an aliphatic dicarboxylic acid having 6 carbon atoms.

[0044] (B-2) The content of component (B-2) is preferably 0.1% by mass or more, 0.5% by mass or more, or 1% by mass or more, based on the total amount of the topical skin composition, and also preferably 15% by mass or less, 10% by mass or less, 5% by mass or less, or 3% by mass or less, based on the viewpoint of further enhancing the effects of the present invention.

[0045] The mass ratio of the content of component (B-2) to the content of component (A) {content of component (B-2) / content of component (A)} is preferably 0.5 or more, 1 or more, 1.5 or more, or 2 or more, and also preferably 10 or less, 8 or less, or 5 or less.

[0046] (B-3) Compounds having a pyrrolidone ring group (hereinafter also referred to as "component (B-3)") include pyrrolidone carboxylic acid or its salts, polymers having a pyrrolidone ring group, and the like.

[0047] The salt of pyrrolidone carboxylic acid may be a metal salt such as a sodium salt or a potassium salt, and is preferably a sodium salt (sodium pyrrolidone carboxylic acid). The polymer having a pyrrolidone ring group is preferably polyvinylpyrrolidone (PVP).

[0048] The viscosity property value (K value) of polyvinylpyrrolidone is not particularly limited, but is preferably 5 or higher, 15 or higher, or 25 or higher, and also preferably 100 or lower, 50 or lower, or 35 or lower.

[0049] (B-3) Component is preferably at least one selected from the group consisting of pyrrolidone carboxylic acid or a salt thereof and polyvinylpyrrolidone, and more preferably at least one selected from the group consisting of sodium pyrrolidone carboxylic acid and polyvinylpyrrolidone.

[0050] (B-3) The content of component (B-3) is preferably 0.1% by mass or more, 0.5% by mass or more, or 1% by mass or more, based on the total amount of the topical skin composition, and also preferably 15% by mass or less, 10% by mass or less, 5% by mass or less, 3% by mass or less, or 1% by mass or less, based on the viewpoint of further enhancing the effects of the present invention.

[0051] The mass ratio of the content of component (B-3) to the content of component (A) {content of component (B-3) / content of component (A)} is preferably 0.5 or more, 1 or more, or 1.5 or more, and also preferably 5 or less, 3 or less, or 2 or less.

[0052] The topical skin composition according to this embodiment may further contain at least one selected from the group consisting of (C) dihydric alcohols having 3 to 6 carbon atoms and monohydric alcohols having 2 or 3 carbon atoms (hereinafter also referred to as "component (C)"). The inclusion of component (C) in the topical skin composition makes azelaic acid even more soluble. From the viewpoint of further enhancing the effects of the present invention, component (C) is preferably a dihydric alcohol having 3 to 6 carbon atoms.

[0053] (C) The dihydric alcohol having 3 to 6 carbon atoms is preferably dipropylene glycol, 1,3-propanediol, propylene glycol (propane-1,2-diol), or butylene glycol (1,3-butanediol). Among these, dipropylene glycol is preferred from the viewpoint of stably containing azelaic acid. (C) The monohydric alcohol having 2 or 3 carbon atoms is preferably ethanol or isopropanol.

[0054] (C) The content of component (C) is preferably 5% by mass or more, 10% by mass or more, or 20% by mass or more, based on the total amount of the topical skin composition, and also preferably 70% by mass or less, 60% by mass or less, or 40% by mass or less, from the viewpoint of further enhancing the effects of the present invention.

[0055] The topical skin composition according to this embodiment may further contain water. Examples of water include distilled water, purified water, hot spring water, and deep-sea water. The water content may be 20% by mass or more, 30% by mass or more, or 40% by mass or more, and may be 90% by mass or less, 80% by mass or less, or 70% by mass or less, based on the total amount of the topical skin composition.

[0056] The pH of the topical skin composition according to this embodiment may be 2 or higher, 2.5 or higher, or 3 or higher, and may be 8 or lower, 7 or lower, 6 or lower, 5.7 or lower, 5.5 or lower, or 5.3 or lower.

[0057] When the topical skin composition according to this embodiment is used for the prevention, improvement, and / or treatment of acne, the pH of the topical skin composition according to this embodiment is preferably 5.7 or less, more preferably 5.5 or less, and even more preferably 5.3 or less.

[0058] The topical skin composition of this embodiment may be a pharmaceutical, quasi-drug, or cosmetic. The form of the topical skin composition used for pharmaceutical purposes is not particularly limited and examples include liquids, suspensions, emulsions, creams, ointments, gels, liniments, lotions, and aerosols. These formulations can be manufactured according to the methods described in the General Provisions of the 18th Revised Japanese Pharmacopoeia. Among the forms of topical skin compositions used for pharmaceutical purposes, liquids, emulsions, and lotions are preferred.

[0059] When used as a topical skin composition for quasi-drugs or cosmetics, it can be in the same form as the topical skin composition for pharmaceuticals described above. Among the forms of topical preparations used as quasi-drugs or cosmetics, liquids, emulsions, and lotions are preferred.

[0060] When used as a quasi-drug or cosmetic external skin composition, examples of uses include basic cosmetics such as lotions, emulsions, gels, creams, serums, pads, sunscreens, hand creams, body lotions, and body creams; and cleansing cosmetics such as facial cleansers, makeup removers, shaving agents, body washes, shampoos, conditioners, and treatments. Among these uses, lotions, serums, and body lotions are preferred when used as a quasi-drug or cosmetic external skin composition.

[0061] The topical skin composition of this embodiment may contain other ingredients that are commonly used in pharmaceuticals, quasi-drugs, or cosmetics, as long as they do not impair the effects of the present invention. Examples of such ingredients include other active ingredients or ingredients equivalent to additives.

[0062] Other active ingredients include, for example, moisturizing ingredients, anti-inflammatory ingredients, antibacterial ingredients, vitamins, peptides or their derivatives, amino acids or their derivatives, cell-activating ingredients, anti-aging ingredients, blood circulation promoting ingredients, keratin softening ingredients, whitening ingredients, astringent ingredients, etc.

[0063] Additives include, for example, antioxidants, preservatives, pH adjusters, stabilizers, irritation reducers, colorants, fragrances, and pearlescent finish enhancers.

[0064] The method of using the topical skin composition according to this embodiment varies depending on the condition of the skin, age, and gender of the person using it, but it is sufficient to apply an appropriate amount to the skin several times a day. Because the topical skin composition according to this embodiment contains azelaic acid, it can also be used for the prevention or treatment of acne. It can also be used for the prevention or treatment of rosacea and facial redness. Therefore, in addition to healthy individuals, people with acne, rosacea, or facial redness are suitable users.

[0065] The topical skin composition according to this embodiment, when applied to the skin, also has the effects of refining the skin's texture, conditioning the skin, keeping the skin healthy, and / or preventing skin roughness.

[0066] As another embodiment of the present invention, a method for suppressing the precipitation of azelaic acid in a topical skin composition is provided, comprising the coexistence of (A) azelaic acid, (B-1) an amide derivative of azelaic acid, (B-2) a dicarboxylic acid or salt thereof having 5 to 10 carbon atoms (excluding component (A)), and (B-3) at least one compound selected from the group consisting of compounds having a pyrrolidone ring group, in a topical skin composition. According to this method, the precipitation of azelaic acid over time is suppressed in a topical skin composition in which azelaic acid is dissolved and contained.

[0067] Furthermore, as another embodiment of the present invention, a method for assisting the dissolution of azelaic acid in a topical skin composition is provided, comprising the coexistence of (A) azelaic acid, (B-1) an amide derivative of azelaic acid, (B-2) a dicarboxylic acid or salt thereof having 5 to 10 carbon atoms (excluding component (A)), and (B-3) at least one compound selected from the group consisting of compounds having a pyrrolidone ring group, in the topical skin composition. According to this method, azelaic acid is more easily dissolved in a topical skin composition containing azelaic acid, even when water is used as a medium.

[0068] In the methods according to each of the above embodiments, the specific embodiments of component (A), components (B-1) to (B-3), and other components can be those of the external skin composition described above. [Examples]

[0069] The present invention will be described in more detail below using examples and comparative examples, but the present invention is not limited to the following examples.

[0070] <Test Example 1: Confirmation Test for Azelaic Acid Precipitation> The compositions for the examples and comparative examples were prepared by mixing the ingredients according to the formulations shown in Tables 1 to 5 and stirring at 60°C for 1 hour.

[0071] In the following examples and comparative examples, "(B-1) Azeramidopropyldimethylamine preparation" is a preparation (EPi-On, CORUM) containing a mixture of azeramidopropyldimethylamine (48-52% by mass (standard value, the same applies hereinafter)), 1,3-butanediol (10-15% by mass), and water (35-40% by mass). Also, "(B-1) Azera oil bisdipeptide-10 preparation" is a preparation (BIPURE, Sinerga) containing a mixture of azera oil bisdipeptide-10 (4-6% by mass), potassium citrate (10-15% by mass), glycerin (10-15% by mass), and water (65-75% by mass).

[0072] Each composition was allowed to cool at room temperature until the next day, then stored at 4°C. After storage for a predetermined period, the presence or absence of precipitated crystals in the composition was checked. In Examples 1-1 to 1-13 and Comparative Examples 1-1 to 1-13, the compositions were stored at 4°C, and the presence or absence of precipitated crystals was checked after 1 day and 3 weeks. Furthermore, an overall evaluation was performed according to the evaluation criteria shown below. In Comparative Example 2-3 and Example 2-2, the compositions were stored at 4°C, and the presence or absence of precipitated crystals was checked after 30 minutes. In the other examples, the compositions were stored at 4°C, and the presence or absence of precipitated crystals was checked after 1 day. The evaluation results are shown in Tables 1 to 5. [Evaluation Criteria for Overall Assessment in Examples 1-1 to 1-13 and Comparative Examples 1-1 to 1-13] C: Stored in an environment of 4°C, crystal precipitation was observed after 1 day. B: Stored at 4°C. No crystal precipitation was observed after 1 day, but crystal precipitation was observed after 3 weeks. A: Products that are stored at 4°C and show no crystal precipitation after 3 weeks.

[0073] [Table 1]

[0074] [Table 2]

[0075] [Table 3]

[0076] [Table 4]

[0077] [Table 5]

[0078] As shown in Tables 1 to 5, in the compositions of the examples containing component (B-1), component (B-2), or component (B-3), the precipitation of azelaic acid over time was suppressed even when stored in a low temperature environment of 4°C. However, in the compositions of the comparative examples that do not contain component (B-1), component (B-2), or component (B-3), the precipitation of azelaic acid was observed when stored in the same environment.

[0079] <Test Example 2: Solubility Confirmation Test for Azelaic Acid> The compositions for the Examples and Comparative Examples were prepared by adding the components according to the formulations shown in Tables 6 to 8 and allowing them to stand at 60°C. Note that component (B-1)' in the tables corresponds to a derivative of azelaic acid that does not correspond to component (B-1). During preparation, the azelaic acid dissolves in the solvent as the temperature of the composition rises. The dissolution rates at this time were compared. The state of dissolution was determined visually. For the evaluation of the dissolution rate, for each Example and Comparative Example, a composition without component (B-1) or component (B-1)' was prepared separately as a control. When this control and the compositions for each Example and Comparative Example were stirred under the same conditions, a × was evaluated if the dissolution rate of the composition for each Example and Comparative Example was the same as or slower than the control, and a ○ was evaluated if the dissolution rate of the composition for each Example and Comparative Example was faster than the control. In other words, the method for determining the dissolution rate can also be expressed by the following formula (I). Dissolution rate determination = Dissolution rate [Composition relating to each example and each comparative example] - Dissolution rate [Composition corresponding to each example and each comparative example that does not contain component (B-1) or component (B-1)']...(I) Dissolution rate evaluation: If the result of equation (I) is greater than 0, it is ○; if it is 0 or less, it is ×.

[0080] [Table 6]

[0081] [Table 7]

[0082] [Table 8]

[0083] As shown in Tables 6 to 8, in the compositions of the examples containing component (B-1), azelaic acid dissolved more quickly than in the control composition that did not contain component (B-1). However, in the comparative examples containing component (B-1)', the dissolution rate did not increase compared to the control composition that did not contain component (B-1)'.

Claims

1. (A) Azelaic acid and (B-1) an amide derivative of azelaic acid, (B-2) a dicarboxylic acid or salt thereof having 5 to 10 carbon atoms (excluding component (A) above), and (B-3) a compound having a pyrrolidone ring group, A topical skin composition containing [the specified ingredient].

2. The topical skin composition according to claim 1, wherein the (B-1) component is at least one selected from the group consisting of reaction products of azelaic acid with an amino acid or peptide compound and salts thereof, azelaic acid amidoamine compounds, and azelaic acid alcoholamine compounds.

3. The topical skin composition according to claim 1, wherein the (B-1) component is at least one selected from the group consisting of potassium azeloyl diglycine, azelaic acid lysine, azela oil bisdipeptide-10, azela oil tripeptide-1, azeramidopropyl dimethylamine, and azeramido monoethanolamine.

4. The topical skin composition according to claim 1, wherein the number of carbon atoms in component (B-2) is 5 or more and 8 or less.

5. The topical skin composition according to claim 1, wherein the (B-3) component is at least one selected from the group consisting of pyrrolidone carboxylic acid or a salt thereof, and polyvinylpyrrolidone.

6. The topical skin composition according to any one of claims 1 to 3, wherein the mass ratio of the content of component (B-1) to the content of component (A) is 0.5 or more and 20 or less.

7. The topical skin composition according to claim 1 or 4, wherein the mass ratio of the content of component (B-2) to the content of component (A) is 0.5 or more and 10 or less.

8. The topical skin composition according to claim 1 or 5, wherein the mass ratio of the content of component (B-3) to the content of component (A) is 0.5 or more and 5 or less.

9. The topical skin composition according to any one of claims 1 to 5, wherein component (A) is dissolved in the topical skin composition.

10. (C) The topical skin composition according to any one of claims 1 to 5, further comprising at least one selected from the group consisting of a dihydric alcohol having 3 to 6 carbon atoms and a monohydric alcohol having 2 or 3 carbon atoms.

11. A topical skin composition according to any one of claims 1 to 5, wherein the pH is 2 or higher and 6 or lower.

12. A method for inhibiting the precipitation of azelaic acid in a topical skin composition, A method comprising coexisting in the aforementioned topical skin composition (A) azelaic acid, (B-1) an amide derivative of azelaic acid, (B-2) a dicarboxylic acid or salt thereof having 5 to 10 carbon atoms (excluding component (A)), and (B-3) at least one compound selected from the group consisting of compounds having a pyrrolidone ring group.

13. A method for assisting the dissolution of azelaic acid in a topical skin composition, A method comprising coexisting in the aforementioned topical skin composition (A) azelaic acid, (B-1) an amide derivative of azelaic acid, (B-2) a dicarboxylic acid or salt thereof having 5 to 10 carbon atoms (excluding component (A)), and (B-3) at least one compound selected from the group consisting of compounds having a pyrrolidone ring group.

Images